Doç. Dr. Cihangir Yandım
Mühendislik Fakültesi
Genetik ve Biyomühendislik
Koordinatör, İzmir Ekonomi Üniversitesi
Koordinatör, İzmir Ekonomi Üniversitesi
Doç. Dr. Cihangir Yandım
Mühendislik Fakültesi
Genetik ve Biyomühendislik
Koordinatör, İzmir Ekonomi Üniversitesi
Koordinatör, İzmir Ekonomi Üniversitesi
MAKALELER
SCI, SSCI ve AHCI tarafından taranan dergilerde yayımlanmış veya kabul edilmiş makaleler
Uluslararası
- A.Kıpçak , S.Sezan , Ö.Karpat , E.Kaya , S.Baylan , E.Sarıyar , C.Yandım and Z.Fırtına Karagonlar.
(2024) Suppression of CTC1 inhibits hepatocellular carcinoma cell growth and enhances RHPS4 cytotoxicity.
Molecular Biology Reports , Vol. 51, No. 1, 799-799,
- S.Uyulgan , S.N.Köse , A.Kıpçak , Y.Başkan , G.Dağlar , Z.Fırtına Karagonlar , C.Yandım.
(2024) Thyroid hormone T3 augments the cytotoxicity of sorafenib in Huh7 hepatocellular carcinoma cells by suppressing AKT expression.
Journal Of Cancer Research And Therapeutics , Vol. 20, No. 3, 755-762,
- S.N.Köse , T.Yaraş , A.Bursalı , Y.Oktay , C.Yandım , G.Karakülah.
(2024) Expressions of the satellite repeat HSAT5 and transposable elements are implicated in disease progression and survival in glioma.
Turkish Journal Of Biology , Vol. 48, No. 4, 242-256,
- N.Keske , B.Özay , E.Y.Tükel , M.Menteş , C.Yandım.
(2023) In silico drug screen reveals potential competitive MTHFR inhibitors for clinical repurposing.
Journal Of Biomolecular Structure And Dynamics , Vol. 41, No. 21, 11818-11831,
- M.Menteş , C.Yandım.
(2023) Identification of PPA1 inhibitor candidates for potential repurposing in cancer medicine.
Journal Of Cellular Biochemistry , Vol. 10, No. 124, 1646-1663,
- A.Atik , T.Günal , P.Acar Bozkurt , S.N.Köse , B.Alp , C.Yandım , N.M.Kaleli , G.Kabay and G.Kaleli.
(2023) Characterization of cisplatin loaded hydrophilic glycol chitosan modified eumelanin nanoparticles for potential controlled-release application.
Journal Of Drug Delivery Science And Technology , Vol. Vol 18, No. 104440,
- C.Yandım , G.Karakülah.
(2022) Repeat expression is linked to patient survival and exhibits single nucleotide variation in pancreatic cancer revealing LTR70:r.879A>G.
Gene , Vol. 622, No. 146344,
- M.Menteş , B.Karakuzulu , G.Uçar , C.Yandım.
(2022) Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Computational Biology And Chemistry , Vol. 99, No. 107726,
- G.Karakülah , C.Yandım.
(2021) Identification of differentially expressed genomic repeats in primary hepatocellular carcinoma and their potential links to biological processes and survival.
Turkish Journal Of Biology , Vol. 45, No. 5, 599-612,
- G.Karakülah , C.Yandım.
(2020) Signature changes in the expressions of protein-coding genes, lncRNAs and repeat elements in early and late cellular senescence.
Turkish Journal Of Biology , Vol. 44 , No. 6, 356-370,
- E.Kostaras , T.Kaserer , G.Lazaro , S.Heuss , A.Hussain , P.Casado , A.Hayes , C.Yandım , N.Palaskas , Y.Yu , B.Schwartz , F.Raynaud , Y.Chung , P.Cutillas and I.Vivanco.
(2020) A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
British Journal Of Cancer , Vol. 123, No. 4, 542-555,
- C.Yandım , G.Karakülah.
(2019) Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer.
Cancer Genetics , Vol. 239, 36-45,
- G.Karakülah , N.Arslan , C.Yandım , A.Suner.
(2019) TEffectR: an R package for studying the potential effects of transposable elements on gene expression with linear regression model.
PeerJ , No. 7:e8192,
- C.Yandım , G.Karakülah.
(2019) Expression dynamics of repetitive DNA in early human embryonic development.
BMC Genomics , No. 20,
- T.Natisvili , C.Yandim , R.Silva , G.Emanuelli , F.Krueger , S.Nageshwaran , R.Festenstein.
(2016) Transcriptional activation of pericentromeric satellite repeats and disruption of centromeric clustering upon proteasome inhibiton.
Plos One , Vol. 11, No. 11,
- V.Libri *(equal) , C.Yandim *(equal) , S.Athanasopoulus , N.Loyse , T.Natisvili , P.Law , P.Chan , T.Mohammad , M.Mauri , K.Tam , J.Leiper , S.Piper , A.Ramesh , M.Parkinson , L.Huson , P.Giunti and R.Festenstein.
(2014) Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreichs ataxia: an exploratory, open-label, dose-escalation study.
The Lancet , Vol. 384, No. 9942, 504-513,
- P.Chan , R.Torres , C.Yandim , P.Law , S.Khadayate , M.Mauri , C.Grosan , N.Chapman-Rothe , P.Giunti , M.Pook , R.Festenstein.
(2013) Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreichs ataxia can be reduced upon HDAC inhibition by vitamin B3.
Human Molecular Genetics , Vol. 22, No. 13, 2662-2675,
- C.Yandim , T.Natisvili , R.Festenstein.
(2013) Gene regulation and epigenetics in Friedreichs ataxia.
Journal Of Neurochemistry , No. 126, 21-42,
- P.Wijchers , C.Yandim , E.Panousopoulou , M.Ahmad , N.Harker , A.Saveliev , P.Burgoyne , R.Festenstein.
(2010) Sexual dimorphism in mammalian autosomal gene regulation is determined not only by Sry but by sex chromosome complement as well.
Developmental Cell , Vol. 19, No. 3, 477-484,